NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for ...
Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) ...
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A novel ...
The US Food and Drug Administration (FDA) has approved the Portable Neuromodulation Stimulator (PoNS, Helius Medical Inc) for the short-term treatment of walking impairments as a result of mild to ...
Could a new device called a portable neuromodulation stimulator (PoNS) help improve your mobility and balance with multiple sclerosis? PoNS is a device that delivers mild electrical pulses to two ...
NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), today announced that its Canadian Class II license amendment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback